Pfizer Inc said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the "Eris" subvariant in a study conducted on mice.
Pfizer, along with its German partner BioNTech SE, as well as other COVID-19 vaccine makers Moderna and Novavax have created versions of their shots, which are aimed at the XBB.1.5 subvariant.
EG.5, nicknamed by some as "Eris", is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant.
EG.5 accounted for about more than 17% of COVID-19 cases in the United States, according to the latest government data.
In the United States, COVID-19 related hospitalizations are up more than 40% off of recent lows hit in June, but are still more than 90% below peak levels hit during the January 2022 Omicron outbreak.
EG.5 has also been detected in China, South Korea, Japan and Canada, among other countries.
The World Health Organization classified EG.5 as a "variant of interest", indicating that it should be more closely watched than others because of mutations that might make it more contagious or severe.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
Bullseye! India's Homegrown Glide Bomb 'Gaurav' Hits Target 100 Km Away
Covid-19 Cases Rising Again: WHO Issues Urgent Alert On Potentially Severe Variants Covid-19 Still Driving High Mortality Rate In This Country Biden Returns To White House After Exiting US Presidential Race Vandalism At Kolkata Hospital Where Doctor Was Raped, Tear Gas Fired Starbucks' Indian-Origin CEO, Recently Fired, Never Worked Past 6 pm 150 mg Semen In Kolkata Doctor's Body, Suspect Gang-Rape: Parents To Court Delhi Airport Becomes 1st To Achieve Net Zero Carbon Emission Status US Welcomes India's Engagement In War Between Russia, Ukraine Google Says Iran Hackers Target Trump, Kamala Harris Campaigns Track Latest News Live on NDTV.com and get news updates from India and around the world.